Belite Bio, Inc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BLTE research report →
Range $206 – $303
Price Chart
About the company
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease.
- CEO
- Yu-Hsin Lin
- IPO
- 2022
- Employees
- 41
- HQ
- San Diego, CA, US
Get TickerSpark's AI analysis on BLTE
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $5.17B
- P/E
- -44.54
- Fwd P/E
- 87.98
- PEG
- 1.19
- P/S
- 0.00
- P/B
- 6.63
- EV/EBITDA
- -39.97
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -16.96%
- ROIC
- -17.07%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-84,208,000
- Net Income
- $-77,611,000-114.7%
- EPS
- $-2.31-95.8%
- OCF Growth
- -26.5%
- FCF Growth
- -26.5%
- 52W High
- $200.00
- 52W Low
- $108.00
- 50D MA
- $158.54
- 200D MA
- $159.68
- Beta
- -1.19
- RSI (14)
- 45
- Avg Volume
- 181.17K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Belite Bio said Tinlarebant’s U.S. review is progressing smoothly toward a February 12, 2027 PDUFA date, while the company remains well funded with $774 million in cash and is preparing for global launch.· November 12, 2026
- FDA accepted the Tinlarebant NDA for priority review and set a February 12, 2027 PDUFA date; the company also said the FDA will not hold an advisory committee meeting.
- Belite submitted a Japan J-NDA under Sakigake and also filed in the U.K., Switzerland, and Singapore via the Access Consortium, while planning a measured international rollout.
- Q3 2026 GAAP net loss was $30.3 million versus $21.7 million last year; non-GAAP net loss was $24.3 million versus $8.8 million.
- Cash, cash equivalents and U.S. Treasury bills were $774 million at quarter-end, down modestly from $780 million in Q2 2026.
- Management said pediatric trial start-up is now expected this quarter, before year-end, and that Japan commercialization infrastructure is already being built.
For the third quarter of 2026, Belite reported R&D expense of $15.5 million versus $10.3 million in 2025, and SG&A expense of $21.4 million versus $12.7 million in 2025. On a non-GAAP basis, R&D was $14.7 million versus $8 million, and SG&A was $16.3 million versus $2.1 million. GAAP net loss was $30.3 million compared with $21.7 million a year ago, and non-GAAP net loss was $24.3 million compared with $8.8 million. The company ended the quarter with $774 million in cash, cash equivalents and U.S. Treasury bills, versus $780 million in Q2 2026. Management said that cash runway is sufficient to support potential Tinlarebant commercialization, subject to regulatory approval, and to continue advancing the pipeline.
CEO Yu-Hsin Lin emphasized that 2026 has been a transformative year and framed the company as rapidly advancing on the regulatory front for Tinlarebant. He highlighted priority review, no planned FDA AdCom, the Japan filing, and additional submissions in other markets as steps toward a worldwide rollout. His tone was positive but careful, repeatedly saying the team wants to remain measured and not overspeculate on the label, approvals, or timing beyond the existing milestones.
CFO Hao-Yuan Chuang said the company executed well financially as it prepares for a first potential product launch. He pointed to higher Q3 spending driven mainly by API and drug product manufacturing, consulting fees, sponsorship funding, and professional service fees, with R&D at $15.5 million and SG&A at $21.4 million. He also stressed the balance sheet strength, citing $774 million in cash, cash equivalents and U.S. Treasury bills, and said the current runway should be enough to support potential commercialization if Tinlarebant is approved.
Analysts focused on the FDA process, label expectations, pricing, Japan commercialization, and the GA program. Management said the mid-cycle review has already happened and that the dialogue with FDA has been “incredibly smooth,” but they would not speculate on labeling or the remaining review steps beyond noting that a late-cycle review date is scheduled. On pricing, the company said payers appear supportive and that it still expects rare-disease pricing reflective of unmet need and benchmarking to other rare ophthalmology and pediatric orphan therapies; on Japan, management said it expects to market the drug itself and has already built a local team. For the GA study, management said FDA discussions have been limited and that the interim analysis will come after the February PDUFA milestone.
The call reinforced that Tinlarebant is close to a major regulatory inflection point, with priority review, no AdCom, and management describing FDA interactions as smooth. Belite also has a large cash position, multiple ex-U.S. filings underway, and commercialization preparations already in motion in the U.S. and Japan. Management sounded confident that the addressable Stargardt population is identifiable and that payer interest appears supportive of rare-disease pricing.
The biggest risk remains regulatory: approval is not yet secured, the company would not discuss label details, and there is still uncertainty around the late-cycle review, inspection timing, and the final FDA package. Ex-U.S. rollout and the GA program appear secondary for now, with management explicitly saying resources are concentrated on the U.S. NDA first. The company is also spending heavily ahead of launch, with Q3 expenses and net loss up materially year over year, so execution risk is still high if the approval or launch timeline slips.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 48.1%
- Shares Outstanding
- 40.61M
- Float Shares
- 19.53M
of shares held by institutions
82 13F filers
Buy/sell ratio 0.25. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Darwin Global Management, Ltd. | 3.10M | ▲ 19.91K |
| Paradigm Biocapital Advisors LP | 1.14M | ▼ 90.75K |
| Rtw Investments, LP | 715.33K | 0 |
| Maverick Capital Ltd | 609.91K | ▲ 213.59K |
| Eventide Asset Management, LLC | 390.83K | 0 |
| Millennium Management LLC | 375.07K | ▼ 119.50K |
| Neuberger Berman Group LLC | 247.09K | ▲ 247.09K |
| Affinity Asset Advisors, LLC | 242.09K | ▲ 77.09K |
| Price T Rowe Associates Inc | 202.70K | ▲ 96.84K |
| Logos Global Management LP | 200.00K | ▼ 50.00K |
| Deerfield Management Company, L.P. | 190.00K | ▼ 167.20K |
| Ubs Group AG | 158.40K | ▼ 66.59K |
Held by 16 ETFs
Biggest fund positions in BLTE by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 12, 26 | Scholl Hendrik Peter | sell | 500 |
| Nov 12, 26 | Scholl Hendrik Peter | sell | 500 |
| Nov 12, 26 | Scholl Hendrik Peter | sell | 500 |
| Nov 12, 26 | Scholl Hendrik Peter | sell | 500 |
| Oct 29, 26 | Chuang Hao-Yuan | other | 5,000 |
| Oct 29, 26 | Lin Yu-Hsin | other | 5,000 |
| Sep 24, 26 | Chen Wan-Shan | other | 13,796 |
| Sep 24, 26 | Chen Wan-Shan | other | 13,796 |
| Oct 1, 26 | Scholl Hendrik Peter | sell | 200 |
| Oct 1, 26 | Scholl Hendrik Peter | sell | 24 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BLTE coverage
Recent articles, reports, and earnings notes.
No research on BLTE yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BLTE report →Belite Bio Stock Plunges After FDA Extends Review Timeline
benzinga.com · Nov 20
Belite Bio Announces Extension of FDA Review Timeline for Tinlarebant NDA
globenewswire.com · Nov 20
24,000 Shares in Belite Bio, Inc. Sponsored ADR $BLTE Purchased by Alberta Investment Management Corp
defenseworld.net · Nov 17
What Belite Bio (BLTE) Said on Its Q3 Earnings Call
marketbeat.com · Nov 12
Belite Bio, Inc (BLTE) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 12
Belite Bio Reports Unaudited Third Quarter 2026 Financial Results and Provides a Corporate Update
globenewswire.com · Nov 12
Belite Bio to Host Webcast on November 12, 2026, to Discuss Third Quarter 2026 Financial Results
globenewswire.com · Nov 5
Belite Bio Announces Uplisting to the Nasdaq Global Select Market
globenewswire.com · Oct 19
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.